Previous studies have explored potential biomarkers to predict patient response to https://www.sciencedirect.com/science/article/pii/S0091674918304457 (ICB) treatment, these biomarkers include the expression of checkpoints PD-L1 (23), the tumor mutation burden (TMB) (24), and neoantigen load (25). The gene discussed is CD274; the disease is neoplasm.